Marina Adriana Mercioni

Ms. Marina Adriana Mercioni

General Medicine, University of Medicine and Pharmacy Victor Babes, Timişoara, Timiş, Romania
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
CGChristian Goldis
Christian Goldis
DSDiana Cristiana Sirca
Diana Cristiana Sirca
OBOana Belei
Oana Belei
Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy. Microbiome composition, inflammatory markers (fecal calprotectin, CRP), and disease activity scores (PCDAI/PUCAI) were assessed before and after treatment. At the 3-month follow-up, patients showed significant clinical improvement, with reduced stool frequency (p = 0.004) and improved stool consistency (p < 0.001). Symptoms such as bloating and abdominal pain decreased, while energy levels increased (p < 0.001). Dietary changes included higher fruit, meat, and dairy intake, and lower fast-food and sweets consumption (p < 0.001). Physician assessments classified 90% as “improved”, reinforcing the effectiveness of personalized microbiome interventions. Microbiome-targeted interventions (diet, probiotics, and selective antibiotics) improved pediatric IBD outcomes by reducing pathogenic bacteria and increasing short-chain fatty acid (SCFA)-producing species, lowering inflammation and symptoms. Early-life factors (cesarean birth, and formula feeding) influence IBD risk. Personalized diets enhanced microbial balance. Integrating multi-omics supports precision medicine, offering microbiome-based biomarkers and reducing immunosuppressive reliance.

26 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
CGChristian Goldis
Christian Goldis
DSDiana Cristiana Sirca
Diana Cristiana Sirca
OBOana Belei
Oana Belei
Background/Objectives: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)—an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates. Methods: This was a single-arm, open-label validation trial involving 27 patients with moderate-to-severe IBD who had experienced prior treatment failure. Participants underwent three months of PMM, which included personalized dietary modifications, targeted probiotic supplementation, and antimicrobial interventions based on gut microbiome sequencing. Primary outcomes included stool frequency and consistency as well as inflammatory markers (C-reactive protein and fecal calprotectin), while secondary outcomes assessed nutritional status, metabolic function, and quality of life. Statistical analyses included paired t-tests and repeated measures ANOVA to determine significant changes over time. Results: PMM led to significant clinical improvements, including a 58% reduction in stool frequency (p < 0.001) and improved stool consistency. CRP and fecal calprotectin levels decreased markedly (p < 0.001), suggesting reduced systemic inflammation. Additionally, iron, vitamin B12, and vitamin D deficiencies improved (p < 0.001), alongside weight gain and increased energy levels. Notably, patients on anti-TNF biologics showed enhanced response rates, suggesting potential synergistic effects between microbiome modulation and biologic therapy. Conclusions: This study highlights PMM as a promising adjunctive therapy for IBD, demonstrating benefits across clinical, inflammatory, and metabolic parameters. While findings support the role of microbiome-targeted interventions in disease management, larger randomized controlled trials are required to confirm the long-term efficacy and applicability in broader patient populations.

31 May 2025 in Life
Verified
Journal Article
Open access
PDF file
AGAdrian Goldiș
Adrian Goldiș
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
DSDiana Cristiana Sirca
Diana Cristiana Sirca
CGChristian Goldis
Christian Goldis
OBOana Belei
Oana Belei
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained and targeted-release form of butyrate MSB®) as an adjunct to conventional treatment. Methods: This trial was unicentric, prospective, randomized, and placebo-controlled. An amount of 150 mg sodium butyrate once a day (Group A), or a placebo (Group B) were randomly assigned to patients with ulcerative colitis or Crohn’s disease, aged 7–18 years, who were receiving conventional medication based on the severity of their conditions. Disease activity, C-reactive protein (CRP), and fecal calprotectin concentration differences between the two study groups at 12 weeks of the trial were the main outcomes. Results: With 44 patients in Group A and 44 in Group B, 88 individuals with initially active illness finished the research. Most patients experienced remission by week 12 of the study (36 patients in Group A with sodium butyrate, 81.82%; 21 patients in Group B with placebo, 47.73%). Between the two groups, a significant difference in disease activity was seen (p < 0.001). The sodium butyrate group appeared to have less systemic inflammation than the other group, as evidenced by the significantly lower CRP levels in Group A (18.14 ± 11.19 mg/L) compared to Group B (57.00 ± 33.28 mg/L) at 12 weeks (T2) (p < 0.001). No negative effects were recorded by any of the patients. Fecal calprotectin in Group A dropped much more after 12 weeks (T2) (p < 0.001), suggesting that the sodium butyrate group was better able to regulate intestinal inflammation. Conclusions: In newly diagnosed children and adolescents with IBD, a 12-week sodium butyrate supplementation did demonstrate effectiveness as an additional treatment.

19 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
LHLucian-Flavius Herlo
Lucian-Flavius Herlo
Raluca DumacheRaluca Dumache
Raluca Dumache
DCDuta Ciprian
Duta Ciprian
OVOctavia Vița
Octavia Vița
MMMarina Adriana Mercioni
Marina Adriana Mercioni
SIStela Iurciuc
Stela Iurciuc
Colorectal cancer (CRC) is globally recognized as a prevalent malignancy known for its significant mortality rate. Recent years have witnessed a rising incidence trend in colorectal cancer, emphasizing the necessity for early diagnosis. Our study focused on examining the impact of the SMAD7 gene variant rs4939827 on the risk of colorectal cancer occurrence. The composition of our study group included 340 individuals, comprising 170 CRC diagnosed patients and 170 healthy controls. We performed genotyping of all biological samples using the TaqMan assay on the ABI 7500 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). This investigation focused on the rs4939827 gene variant, assessing its association with CRC risk and clinicopathological characteristics. Genotyping results for the SMAD7 gene variant rs4939827 revealed a 42.6% prevalence of the C allele in CRC patients (p = 0.245) and a 22.8% prevalence of the T allele in control subjects (p = 0.109). This study concluded that there was an elevated risk of CRC in the dominant model for CC/CT+TT, with a p-value of 0.113 and an odds ratio (OR) of 2.781, within a 95% confidence interval (CI) of 0.998 to 3.456. The findings of our research indicate a correlation between variants of the SMAD7 gene and the likelihood of developing colorectal cancer in our study population. Consequently, these results could be instrumental in facilitating early diagnosis of colorectal cancer utilizing information on single-nucleotide polymorphism (SNP) and genetic susceptibility to the disease.

Verified
Journal Article
Open access
PDF file
RDRadu Dragomir
Radu Dragomir
MMMarina Adriana Mercioni
Marina Adriana Mercioni
SNSerban Mircea Negru
Serban Mircea Negru
DPDorel Popovici
Dorel Popovici
SSSorin Saftescu
Sorin Saftescu
ISIoan Sas
Ioan Sas
Background/Objectives: Platinum-resistant ovarian cancer (PROC) is a major therapeutic challenge, as it responds poorly to standard platinum-based treatment, has limited treatment options, and offers a generally unfavorable prognosis. Chemotherapeutic agents like pegylated liposomal doxorubicin (PLD), topotecan (TOPO), and gemcitabine (GEM) are used for this setting, but with varying efficacy and toxicity profiles, leading to an increasing need to understand the optimal balance between treatment effectiveness and tolerability for improving patient outcomes. This study evaluates the efficacy and side effects of PLD, TOPO, and GEM, focusing on progression-free survival (PFS), overall survival (OS), and safety profiles. Methods: We conducted a retrospective observational study that included 856 PROC patients treated with PLD (n = 383), TOPO (n = 352), or GEM (n = 121) at the OncoHelp Oncology Center from January 2018 to December 2023. Inclusion criteria encompass diagnosis, prior platinum therapy, and Eastern Cooperative Oncology Group (ECOG) status (0–2). Treatment protocols followed standard dosing, with adjustments for toxicity. Primary endpoints included PFS and OS, with safety assessed by incidence of grade 3 and 4 toxicities per CTCAE v5.0. Kaplan–Meier analysis and Cox regression were used to compare survival, and statistical significance was set at p < 0.05. Results: TOPO showed higher toxicity than PLD and GEM, including liver damage, hematological and non-hematological side effects, while PLD induced more skin toxicity. In terms of survival, minor differences were seen between the three chemotherapeutic agents, with a slight advantage for PLD for better disease control. Conclusions: Given the comparable results in OS across the regimens, treatment decisions should be based on other factors such as patient tolerance and quality of life.

9 October 2025 in Sensors
Verified
Journal Article
Open access
PDF file
MMMarina Adriana Mercioni
Marina Adriana Mercioni
CCCătălin - Daniel Căleanu
Cătălin - Daniel Căleanu
MUMihai-Eronim-Octavian Ursan
Mihai-Eronim-Octavian Ursan
The background of the article refers to the diagnosis of focal liver lesions (FLLs) through contrast-enhanced ultrasound (CEUS) based on the integration of spatial and temporal information. Traditional computer-aided diagnosis (CAD) systems predominantly rely on static images, which limits the characterization of lesion dynamics. This study aims to assess the effectiveness of Transformer-based architectures in enhancing CAD performance within the realm of liver pathology. The methodology involved a systematic comparison of deep learning models for the analysis of CEUS images and videos. For image-based classification, a Hybrid Transformer Neural Network (HTNN) was employed. It combines Vision Transformer (ViT) modules with lightweight convolutional features. For video-based tasks, we evaluated a custom spatio-temporal Convolutional Neural Network (CNN), a CNN with Long Short-Term Memory (LSTM), and a Video Vision Transformer (ViViT). The experimental results show that the HTNN achieved an outstanding accuracy of 97.77% in classifying various types of FLLs, although it required manual selection of the region of interest (ROI). The video-based models produced accuracies of 83%, 88%, and 88%, respectively, without the need for ROI selection. In conclusion, the findings indicate that Transformer-based models exhibit high accuracy in CEUS-based liver diagnosis. This study highlights the potential of attention mechanisms to identify subtle inter-class differences, thereby reducing the reliance on manual intervention.